Evidence map›Paper›PMID 28801186›Full record

ArticleLancet (London, England)2017

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason and 31 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 184 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 6 pooled it
29.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 6 syntheses or guidelines pooled it, 395 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors at 20 institutions in 10 countries.

Martin J van den BentNeuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
Brigitta BaumertDepartment of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; Department of Radiation-Oncology, University of Münster, Münster, Germany; Paracelsus Clinic, Osnabrück, Germany.
Sara C ErridgeEdinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.
Michael A VogelbaumDepartment of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.
Anna K NowakSchool of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; Co-Operative Group for Neuro-Oncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australia.
Marc SansonSorbonne Universités UPMC, University Paris VI, INSERM, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.
Alba Ariela BrandesMedical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.
Paul M ClementDepartment of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.
Jean Francais BaurainMedical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Warren P MasonPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Helen WheelerNorthern Sydney Cancer Centre, North Shore Hospital, St Leonards, NSW, Australia; Department of Medicine, University of Sydney, Sydney, NSW, Australia.
Olivier L ChinotNeuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.
Sanjeev GillDepartment of Medical Oncology, Alfred Hospital, Melbourne, VIC, Australia.
Matthew GriffinDepartment of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
David G BrachmanDepartment of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
Walter TaalNeuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Roberta RudàDepartment of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.
Michael WellerDepartment of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.
Catherine McBainDepartment of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.
Jaap ReijneveldVUmc Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.
Roelien H EntingDepartment of Neurology, UMCG, University of Groningen, Groningen, Netherlands.
Damien C WeberDepartment of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.
Thierry LesimpleDepartment of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.
Susan ClentonWeston Park Hospital, Sheffield, UK.
Anja GijtenbeekDepartment of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.
Sarah PascoeDepartment of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.
Ulrich HerrlingerDivision of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical Centre, Bonn, Germany.
Peter HauWilhelm Sander-Neuro-Oncology Unit and Department of Neurology, University Hospital Regensburg, Regensburg, Germany.
Frederic DhermainRadiotherapy Department, Gustave Roussy University Hospital, Villejuif, France.
Irene van HeuvelNeuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Roger StuppDepartment of Medical Oncology, University Hospital and University of Zurich, Zurich, Switzerland.
Ken AldapePrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Hendrikus Jan DubbinkDepartment of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Winand N M DinjensDepartment of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Pieter WesselingDepartment of Pathology, VU University Medical Centre, Amsterdam, Netherlands; Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands.
Sarah NuyensEORTC, Brussels, Belgium.
Vassilis GolfinopoulosEORTC, Brussels, Belgium.
Thierry GorliaEORTC, Brussels, Belgium.
Wolfgang WickNeurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.
Johan M KrosDepartment of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Erasmus MC Cancer Institute · NLEuropean Organisation for Research and Treatment of Cancer · BERadboud University Medical Center · NLUniversity Hospital of Zurich · CHUniversity of Sydney · AUAcademic Medical Center · NLAix-Marseille Université · FRBarrow Neurological Institute · USCase Western Reserve University · USCentre Eugène Marquis · FRHeidelberg University · DEInstitut Gustave Roussy · FRIstituto delle Scienze Neurologiche di Bologna · ITMayo Clinic in Arizona · USNottingham University Hospitals NHS Trust · GBPiedmont Reference Center for Epidemiology and Cancer Prevention · ITPrincess Margaret Cancer Centre · CASorbonne Université · FRThe Alfred Hospital · AUThe Christie NHS Foundation Trust · GB

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
RTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4M
Cancer Research UK 7267Medical Research Council MC_U122861383Medical Research Council MC_UU_12023/10Medical Research Council MC_UU_12023/20Medical Research Council MC_UU_12023/28NCI NIH HHS U10 CA021661NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067
6 · The paper itself

Abstract

backgroundThe role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.

methodsThis was a phase 3, randomised, open-label study with a 2 × 2 factorial design. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with WHO performance status scores of 0-2. The randomisation schedule was generated with the electronic EORTC web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the minimisation technique, to receive radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy) alone or with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m

findingsAt the time of the interim analysis, 745 (99%) of the planned 748 patients had been enrolled. The hazard ratio for overall survival with use of adjuvant temozolomide was 0·65 (99·145% CI 0·45-0·93). Overall survival at 5 years was 55·9% (95% CI 47·2-63·8) with and 44·1% (36·3-51·6) without adjuvant temozolomide. Grade 3-4 adverse events were seen in 8-12% of 549 patients assigned temozolomide, and were mainly haematological and reversible.

interpretationAdjuvant temozolomide chemotherapy was associated with a significant survival benefit in patients with newly diagnosed non-co-deleted anaplastic glioma. Further analysis of the role of concurrent temozolomide treatment and molecular factors is needed.

fundingSchering Plough and MSD.

Identifiers

PMID28801186
PMCPMC5806535
OpenAlexW2744160381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.